1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
No clear rationale for use of glucosamine as yet |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
GI diseases present a monumental economic burden |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 5-6
Sushma Soni,
Preview
|
|
摘要:
Gastrointestinal (GI) diseases pose a monumental burden in the US in terms of both the annual number of cases and costs, according to the results of a study commissioned by the American Gastroenterological Association (AGA) and conducted by The Lewin Group.*The study assessed the prevalence and cost of only a small proportion of GI diseases and found that these diseases alone affect > 283 million patients per year and are associated with direct and indirect costs totalling an estimated $US42 billion. Data from the study were presented at a news conference at Digestive Disease Week 2001 [Atlanta, US; May 2001], where Professor Mark Donowitz from Johns Hopkins University, Baltimore, US, described this economic burden as'shockingly large'.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
Inflammatory bowel disease: drugs cost $US7 million/year in Sweden |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Antibacterials offer no QOL gain over placebo in Lyme disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
New drugs delay bone metastases in prostate cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 8-9
Carmen Innes,
Preview
|
|
摘要:
Two new drugs appear to offer palliative relief from painful bone metastases associated with advanced prostate cancer, improving patients' quality of life (QOL) and slowing disease progression. Study data for the 2 drugs, atrasentan [ABT 627] and clodronic acid, were reported recently at the 37th Annual Meeting of the American Society of Clinical Oncology [San Francisco, US; May 2001].
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Vasoactive intestinal peptide prevents experimental arthritis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Paroxetine - relief for both men and women with PTSD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1293,
2001,
Page 11-12
Ed Susman,
Preview
|
|
摘要:
Intrusive thoughts and other symptoms that adversely affect patients with post-traumatic stress disorder (PTSD) can be relieved by treatment with paroxetine ['Paxil'], researchers said at the 154th Annual Meeting of the American Psychiatric Association [New Orleans, US; May 2001]. In a series of studies, the selective serotonin reuptake inhibitor (SSRI) paroxetine was more effective than placebo at relieving the symptoms of PTSD in both men and women. The drug was launched in Europe earlier this month, making it the only approved therapy for PTSD in Europe, and is currently under review by the US FDA. Sertraline is the only medication approved in the US for the treatment of PTSD; however, there is controversy regarding its benefits in men, as efficacy has only been definitively shown in women.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|